Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?

EuroIntervention. 2009 Aug;5(3):325-9. doi: 10.4244/51.

Abstract

Aims: We assessed prospectively the association between occurrence of post-discharge non-CABG-related TIMI major and minor bleeding and post-treatment platelet reactivity in patients with non-ST elevation acute coronary syndrome (NSTE ACS).

Methods and results: Five hundred and ninety-seven consecutive patients admitted with NSTE ACS were prospectively included. Between hospital discharge and one month follow-up, we observed 16 (2.7%) non-CABG-related TIMI haemorrhagic complications including five (0.84%) major and 11 (1.8%) minor bleeds. Patients with bleeding had significantly lower post-treatment values of ADP-induced aggregation (43+/-14% versus. 56+/-19%, p=0.002) and platelet reactivity index VASP (43+/-14% versus 54+/-23%; p=0.04) and a trend for lower values of arachidonic acid-induced aggregation (2.4+/-5.4 versus 13+/-21; p=0.27). After stratification by quartiles based on post-treatment ADP-induced platelet aggregation, we identified patients in the first quartile as hyper-responders with very low post-treatment platelet reactivity, below <40%. The risk of TIMI major and minor bleeding was significantly higher in the first quartile of hyper-responders than in the others quartiles: 10 (6.6%) versus six (1.4%), p=0.001.

Conclusions: Our results suggest that assessment of post-treatment platelet reactivity might be used to detect hyper-responders to antiplatelet therapy with higher risk of non-CABG related bleeding and tailor antiplatelet therapy according to both ischaemic and bleeding risk.

MeSH terms

  • Acute Coronary Syndrome / blood
  • Acute Coronary Syndrome / drug therapy*
  • Acute Coronary Syndrome / surgery*
  • Adenosine Diphosphate
  • Aged
  • Arachidonic Acid
  • Aspirin / adverse effects*
  • Biomarkers / blood
  • Cell Adhesion Molecules / blood
  • Clopidogrel
  • Coronary Artery Bypass*
  • Drug Therapy, Combination
  • Female
  • Gastrointestinal Hemorrhage / blood
  • Gastrointestinal Hemorrhage / chemically induced
  • Hemorrhage / blood
  • Hemorrhage / chemically induced*
  • Humans
  • Intracranial Hemorrhages / blood
  • Intracranial Hemorrhages / chemically induced
  • Male
  • Microfilament Proteins / blood
  • Middle Aged
  • Patient Discharge*
  • Phosphoproteins / blood
  • Phosphorylation
  • Pilot Projects
  • Platelet Activation / drug effects*
  • Platelet Aggregation Inhibitors / adverse effects*
  • Platelet Function Tests
  • Predictive Value of Tests
  • Prospective Studies
  • Risk Assessment
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives*
  • Time Factors
  • Treatment Outcome

Substances

  • Biomarkers
  • Cell Adhesion Molecules
  • Microfilament Proteins
  • Phosphoproteins
  • Platelet Aggregation Inhibitors
  • vasodilator-stimulated phosphoprotein
  • Arachidonic Acid
  • Adenosine Diphosphate
  • Clopidogrel
  • Ticlopidine
  • Aspirin